Target intelligence / Profile preview

Granzyme-mediated cytotoxicity

Molecular classification
Other (cytotoxic effector mechanism)
01

Overview

Granzyme-mediated cytotoxicity is an essential immune defense mechanism whereby cytotoxic T lymphocytes and natural killer cells eliminate virus-infected cells, tumor cells, and other abnormal targets by releasing specialized secretory granules containing perforin and multiple serine proteases called *granzymes* into the immunological synapse formed with their target. Perforin forms pores in the target cell membrane that allow entry of granzymes into the cytosol. Once inside, different granzymes trigger programmed cell death through various mechanisms: • Apoptosis: Most notably via caspase activation by Granzyme B. • Pyroptosis: Via cleavage/activation of gasdermin family members by certain granzymes such as Granzyme A. • Disruption of DNA repair pathways. • Induction/inhibition of inflammatory responses depending on context. This process is critical for controlling infections and preventing malignancy but can also contribute to pathological inflammation if dysregulated.

Other names
Granule exocytosis pathwayCytolytic granule-mediated cell deathPerforin/granzyme pathway
02

Mechanism of action

For drugs targeting this system indirectly (e.g., immune checkpoint inhibitors): - Enhancement of T cell/NK cell activation increases release of perforin and granzymes. - Potential future approaches may include direct inhibition/activation of specific granzymes.

03

Biological functions

Immune responseCell deathApoptosis inductionPyroptosis inductionAntiviral defenseAntitumor activity
04

Disease associations

CancerInfection/viral diseasesAutoimmune diseaseInflammatory diseases
05

Safety considerations

Excessive activation can lead to tissue damage and contribute to autoimmune pathology; insufficient activity may result in poor tumor clearance or viral persistence. Off-target effects could include unwanted apoptosis/pyroptosis in healthy tissues.
06

Biomarkers

Elevated levels of granzyme proteins—especially Granzyme B—in blood/tissue can serve as biomarkers for immune activation status in cancer immunotherapy and autoimmune/infectious diseases

Beyond the preview

Go deeper on Granzyme-mediated cytotoxicity.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Granzyme-mediated cytotoxicity.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call